Telangiectasis: Clinical Trials

6 trials for Telangiectasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 36Terminated 6
Phase 22Terminated 2

Follow Telangiectasis: new trials by email Literature Review of Telangiectasis trials Research Report on Telangiectasis

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open-Label Extension of EryDex Study IEDAT-04-2022
Dexamethasone sodium phosphate - Ataxia Telangiectasia
Phase 3TerminatedQuince Therapeutics S.p.A.1012024-12-112026-05-05
Propranolol for Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients
Propranolol treatment, Placebo - Hereditary Hemorrhagic Telangiectasia, Osler Weber Rendu Disease
Phase 3TerminatedUniversity Hospital, Bordeaux152020-06-232026-06-23
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
Anti-VEGF injections of bevacizumab, Laser - Retinal Telangiectasis, Coats Disease
Phase 3TerminatedFondation Ophtalmologique Adolphe de Rothschild182019-10-242025-12-10
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
EryDex System - Ataxia Telangiectasia, Genetic Syndrome
Phase 3TerminatedQuince Therapeutics S.p.A.1042018-06-122024-10-08
Exparel as a Nerve Block for Severe Hand Pain
liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease
Phase 2 / Phase 3TerminatedJose Soberon, MD132014-11-012024-05-21
Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Bevacizumab, placebo - Hereditary Hemorrhagic Telangiectasia, Epistaxis
Phase 2 / Phase 3TerminatedHospices Civils de Lyon802014-04-012015-11-20

Narrower conditions

Ataxia Telangiectasia (2)  ·  Epistaxis (2)  ·  Telangiectasia, Hereditary Hemorrhagic (2)  ·  CREST Syndrome (1)  ·  Genetic Diseases, Inborn (1)  ·  Peripheral Vascular Diseases (1)  ·  Raynaud Disease (1)  ·  Retinal Telangiectasis (1)  ·  Scleroderma, Diffuse (1)

Broader conditions

Cardiovascular Diseases (6)  ·  Vascular Diseases (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Metabolic Diseases (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Ataxia (2)  ·  Brain Diseases (2)  ·  Cardiovascular Abnormalities (2)  ·  Central Nervous System Diseases (2)  ·  Cerebellar Ataxia (2)  ·  Cerebellar Diseases (2)  ·  Congenital Abnormalities (2)  ·  DNA Repair-Deficiency Disorders (2)  ·  Dyskinesias (2)

Interventions

Bevacizumab (1)  ·  Lasers (1)  ·  dexamethasone 21-phosphate (1)

Sponsors

Quince Therapeutics S.p.A. (2)  ·  Fondation Ophtalmologique Adolphe de Rothschild (1)  ·  Hospices Civils de Lyon (1)  ·  Jose Soberon, MD (1)  ·  University Hospital, Bordeaux (1)

Countries

France (3)  ·  United States (3)  ·  Germany (2)  ·  Italy (2)  ·  Norway (2)  ·  Poland (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Belgium (1)  ·  Denmark (1)  ·  India (1)  ·  Switzerland (1)  ·  Tunisia (1)

Top investigators

Dirk Thye, MD (1)  ·  Guenter R Janhofer, MD, PhD (1)  ·  Jose Soberon, MD (1)

Results publications

PMID 27599328, PMID 39917433

NIH funding

2016 (1), 2018 (1)